Abstract:Thioredoxin-interacting protein (TXNIP) is induced by high glucose (HG), whereupon it acts to inhibit thioredoxin, thereby promoting oxidative stress. We have found that TXNIP knockdown in human renal tubular cells helped prevent the epithelial-to-mesenchymal transition (EMT). Here, we studied the potential effect of TXNIP on podocyte phenotypic alterations in diabetic nephropathy (DN) in vivo and in vitro. In conditionally immortalized mouse podocytes under HG conditions, knocking down TXNIP disrupted EMT, reactive oxygen species (ROS) production, and mammalian target of rapamycin (mTOR) pathway activation. Further, Raptor short hairpin RNA (shRNA), Rictor shRNA, and mTOR specific inhibitor KU-0063794 were used to assess if the mTOR signal pathway is involved in HG-induced EMT in podocytes. We found that Raptor shRNA, Rictor shRNA, and KU-0063794 could all restrain HG-induced EMT and ROS production in podocytes. In addition, antioxidant Tempol or N-acetylcysteine presented a prohibitive effect on HG-induced EMT in podocytes. Streptozotocin was utilized to render equally diabetic in wild-type (WT) control and TXNIP (-/-) (TKO) mice. Diabetes did not increase levels of 24-hr urinary protein, serum creatinine, blood urea nitrogen, and triglyceride in TXNIP (-/-) mice. Podocyte phenotypic alterations and podocyte loss were detected in WT but not in TKO diabetic mice. Oxidative stress was also suppressed in diabetic TKO mice relative to WT controls. Also, TXNIP deficiency suppresses the activation of mTOR in glomeruli of streptozotocin-induced diabetic mice. Moreover, TXNIP expression, mTOR activation, Nox1, and Nox4 could be detected in renal biopsy tissues of patients with DN. This suggests that decreased TXNIP could ameliorate phenotypic alterations of podocytes via inhibition of mTOR in DN, highlighting TXNIP as a promising therapeutic target.

Thioredoxin-Interacting Protein as a Novel Potential Therapeutic Target in Diabetes Mellitus and Its Underlying Complications

Overview on Thioredoxin-Interacting Protein (TXNIP): A Potential Target for Diabetes Intervention

Thioredoxin Interacting Protein Inhibitors in Diabetes Mellitus: A Critical Review

Diabetes pathogenic mechanisms and potential new therapies based upon a novel target called TXNIP

TXNIP inhibition in the treatment of type 2 diabetes mellitus: design, synthesis, and biological evaluation of quinazoline derivatives

TXNIP inhibition in the treatment of diabetes. Verapamil as a novel therapeutic modality in diabetic patients

Thioredoxin-interacting protein: a critical link between glucose toxicity and beta-cell apoptosis

A novel class of oral, non-immunosuppressive, beta cell-targeting, TXNIP-inhibiting T1D drugs is emerging

An update on the role of thioredoxin-interacting protein in diabetic kidney disease: A mini review

Relationship between Thioredoxin Interacting Protein and Diabetes Mellitus

TXNIP: A key protein in the cellular stress response pathway and a potential therapeutic target

Thioredoxin-Interacting Protein Deficiency Alleviates Phenotypic Alterations Of Podocytes Via Inhibition Of Mtor Activation In Diabetic Nephropathy

Drug Repurposing for Thioredoxin Interacting Protein Through Molecular Networking, Pharmacophore Modelling, and Molecular Docking Approaches

Thioredoxin-interacting protein regulates insulin transcription through microRNA-204

TXNIP regulates peripheral glucose metabolism in humans

Thioredoxin1 Inactivation Mediates the Impairment of Ischemia-Induced Angiogenesis and Further Injury in Diabetic Myocardium

The Emerging Role of TXNIP in Ischemic and Cardiovascular Diseases; A Novel Marker and Therapeutic Target

TXNIP deficiency mitigates podocyte apoptosis via restraining the activation of mTOR or p38 MAPK signaling in diabetic nephropathy

TXNIP: A Double-Edged Sword in Disease and Therapeutic Outlook

Thioredoxin-interacting protein: A new therapeutic target in bone metabolism disorders?